{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:08:35Z","timestamp":1792112915658,"version":"4.4.0"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T00:00:00Z","timestamp":1516579200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"DOI":"10.3389\/fnins.2017.00741","type":"journal-article","created":{"date-parts":[[2018,1,22]],"date-time":"2018-01-22T12:26:19Z","timestamp":1516623979000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":97,"title":["The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment"],"prefix":"10.3389","volume":"11","author":[{"given":"Alex T.","family":"Raben","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria S.","family":"Marshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araba","family":"Chintoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Gorbovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret K.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,1,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.euroneuro.2013.04.010","article-title":"Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching","volume":"23","author":"Agid","year":"","journal-title":"Eur. Neuropsychopharmacol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.euroneuro.2012.10.005","article-title":"Early prediction of clinical and functional outcome in schizophrenia","volume":"23","author":"Agid","year":"","journal-title":"Eur. Neuropsychopharmacol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00115-006-2112-0","article-title":"Neuere Antipsychotika","volume":"78","author":"Aichhorn","year":"2007","journal-title":"Unterschiede im Nebenwirkungsprofil bei Frauen und M\u00e4nnern. Nervenarzt"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","article-title":"A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers","volume":"6","author":"Albaugh","year":"2011","journal-title":"PLoS ONE"},{"key":"B5","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature","volume":"62","author":"Allison","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"B6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"B7","first-page":"182","article-title":"Drug-produced obesity. Experiences with chlorpromazine, perphenazine and clopenthixol","volume":"11","author":"Amdisen","year":"1964","journal-title":"Dan. Med. Bull"},{"key":"B8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/0269881105058978","article-title":"Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic","volume":"19","author":"Ascher-Svanum","year":"","journal-title":"J. Psychopharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-244X-5-3","article-title":"Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia","volume":"5","author":"Ascher-Svanum","year":"","journal-title":"BMC Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1176\/ajp.2006.163.7.1276","article-title":"Association of initial antipsychotic response to clozapine and long-term weight gain","volume":"163","author":"Bai","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1176\/ps.50.5.704","article-title":"Weight gain among patients on clozapine","volume":"50","author":"Bai","year":"1999","journal-title":"Psychiatr. Serv"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e94112","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLoS ONE"},{"key":"B13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pharmthera.2012.07.006","article-title":"Insulin in the brain: there and back again","volume":"136","author":"Banks","year":"2012","journal-title":"Pharmacol. Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with Schizophrenia treated with Olanzapine, Haloperidol, or Risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1007\/s00213-016-4324-8","article-title":"Atypical antipsychotics and effects on feeding: from mice to men","volume":"233","author":"Benarroch","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.pnpbp.2012.03.001","article-title":"Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain","volume":"38","author":"Brandl","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.psychres.2014.05.031","article-title":"No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain","volume":"219","author":"Brandl","year":"2014","journal-title":"Psychiatry Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4088\/JCP.v66n0208","article-title":"Effects of behavioral therapy on weight loss in overweight and obese patients with Schizophrenia or Schizoaffective disorder","volume":"66","author":"Brar","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"B19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4684-5380-5_16","article-title":"Insulin receptors in brain development","volume-title":"Insulin, Insulin-like Growth Factors, and Their Receptors in the Central Nervous System","author":"Brennan","year":"1987"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/j.1742-1241.2009.02224.x","article-title":"Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies","volume":"63","author":"Bushe","year":"2009","journal-title":"Int. J. Clin. Pract"},{"key":"B21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1176\/ajp.153.6.817","article-title":"Differential effect of clozapme on weight: a controlled study","volume":"153","author":"Bustillo","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.ijo.0803222","article-title":"Weight loss in overweight patients maintained on atypical antipsychotic agents","volume":"30","author":"Centorrino","year":"2006","journal-title":"Int. J. Obes"},{"key":"B23","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/ng.156","article-title":"Common genetic variation near MC4R is associated with waist circumference and insulin resistance","volume":"40","author":"Chambers","year":"2008","journal-title":"Nat. Genet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.psychres.2013.08.056","article-title":"Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia","volume":"210","author":"Chen","year":"2013","journal-title":"Psychiatry Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/01.jcp.0000237947.80764.d9","article-title":"The early effect of Olanzapine and Risperidone on insulin secretion in Atypical-native Schizophrenic patients","volume":"26","author":"Chiu","year":"2006","journal-title":"J. Clin. Psychopharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.neuron.2008.04.014","article-title":"Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo","volume":"58","author":"Chiu","year":"2008","journal-title":"Neuron"},{"key":"B27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/tpj.2011.66","article-title":"Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene","volume":"13","author":"Chowdhury","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation Antipsychotic medications during first-time use in children and Adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ejcn.2013.253","article-title":"The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity","volume":"68","author":"Cuerda","year":"2013","journal-title":"Eur. J. Clin. Nutr"},{"key":"B30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/00004714-200206000-00003","article-title":"Antipsychotic-induced weight gain and Therapeutic response: a differential association","volume":"22","author":"Czobor","year":"2002","journal-title":"J. Clin. Psychopharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.schres.2006.04.010","article-title":"Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia","volume":"86","author":"Fan","year":"2006","journal-title":"Schizophr. Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/PSY.0b013e318230343f","article-title":"Testosterone in newly diagnosed, Antipsychotic-naive men with nonaffective Psychosis","volume":"73","author":"Fernandez-Egea","year":"2011","journal-title":"Psychosom. Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1176\/appi.ajp.2010.09091328","article-title":"The effects of hypertension and body mass index on cognition in Schizophrenia","volume":"167","author":"Friedman","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.eurpsy.2003.06.002","article-title":"Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels","volume":"18","author":"Garyfallos","year":"2003","journal-title":"Eur. Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"J. Psychiatr. Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/01.psy.0000174994.91245.34","article-title":"Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical Antipsychotics","volume":"67","author":"Gilles","year":"2005","journal-title":"Psychosom. Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/mp.2008.40","article-title":"Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway","volume":"13","author":"Girgis","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/archpsyc.1964.01720200083012","article-title":"Weight change during and after hospital treatment","volume":"10","author":"Gordon","year":"1964","journal-title":"Arch. Gen. Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/JCP.0b013e31819359be","article-title":"Polymorphisms of the LEP- and LEPR gene and obesity in patients using Antipsychotic medication","volume":"29","author":"Gregoor","year":"2009","journal-title":"J. Clin. Psychopharmacol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.schres.2013.02.023","article-title":"Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: an animal model","volume":"146","author":"Guenette","year":"2013","journal-title":"Schizophr. Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/00004714-199906000-00014","article-title":"Olanzapine: weight gain and therapeutic efficacy","volume":"19","author":"Gupta","year":"1999","journal-title":"J. Clin. Psychopharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","article-title":"Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model","volume":"131","author":"Hahn","year":"2011","journal-title":"Schizophr. Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/JCP.0b013e31829e8333","article-title":"Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls","volume":"33","author":"Hahn","year":"2013","journal-title":"J. Clin. Psychopharmacol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2337\/dc06-1063","article-title":"Acute insulin response and \u03b2-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks","volume":"30","author":"Hardy","year":"2007","journal-title":"Diabetes Care"},{"key":"B45","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.diabres.2004.07.005","article-title":"Weight gain during insulin therapy in patients with type 2 diabetes mellitus","volume":"65","author":"Heller","year":"2004","journal-title":"Diabetes Res. Clin. Pract"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.4088\/JCP.0507e12","article-title":"Series introduction and cardiovascular disease in patients with schizophrenia","volume":"68","author":"Hennekens","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.schres.2011.01.022","article-title":"The association between weight change and symptom reduction in the CATIE schizophrenia trial","volume":"128","author":"Hermes","year":"2011","journal-title":"Schizophr. Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0033-3182(70)71576-4","article-title":"Weight changes with Schizophrenic Psychosis and Psychotropic drug therapy","volume":"11","author":"Holden","year":"1970","journal-title":"Psychosomatics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2217\/pgs.15.155","article-title":"Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response","volume":"17","author":"Huang","year":"2016","journal-title":"Pharmacogenomics"},{"key":"B51","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0924-977X(95)80001-I","article-title":"Weight gain induced by clozapine","volume":"5","author":"Hummer","year":"1995","journal-title":"Eur. Neuropsychopharmacol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.pnpbp.2010.08.002","article-title":"Sex differences in the association of weight gain and risperidone efficacy among schizophrenic patients","volume":"34","author":"Hung","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2165\/00044011-199612010-00003","article-title":"Weight gain as a predictor of long term clozapine efficacy","volume":"12","author":"Jalenques","year":"1996","journal-title":"Clin. Drug Investig"},{"key":"B54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1055\/s-0030-1263174","article-title":"Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with Schizophrenia","volume":"44","author":"Jassim","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"B55","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/00005053-194810850-00007","article-title":"Variations of body weight and menstruation in mental illness and their relation to shock treatmentS*","volume":"108","author":"Kalinowsky","year":"1948","journal-title":"J. Nerv. Ment. Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant Schizophrenic: a double-blind comparison with Chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-017-0820-z","article-title":"The microbiome-gut-brain axis: implications for schizophrenia and antipsychotic induced weight gain","author":"Kanji","year":"2017","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1089\/cap.2012.0099","article-title":"Associations among obesity, acute weight gain, and response to treatment with Olanzapine in Adolescent Schizophrenia","volume":"23","author":"Kemp","year":"2013","journal-title":"J. Child Adolesc. Psychopharmacol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/01.jcp.0000161501.65890.22","article-title":"Association between early and rapid weight gain and change in weight over one year of Olanzapine therapy in patients with Schizophrenia and related disorders","volume":"25","author":"Kinon","year":"2005","journal-title":"J. Clin. Psychopharmacol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.schres.2008.09.023","article-title":"Differences in glucose tolerance between deficit and nondeficit schizophrenia","volume":"107","author":"Kirkpatrick","year":"2009","journal-title":"Schizophr. Res"},{"key":"B61","first-page":"322","article-title":"Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone","volume":"34","author":"Konarzewska","year":"2013","journal-title":"Neuro. Endocrinol. Lett."},{"key":"B62","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4088\/JCP.13m08711","article-title":"Cause and rate of death in people with Schizophrenia across the lifespan","volume":"75","author":"Kredentser","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"B63","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2174\/1871527311312050010","article-title":"Neuropeptide Systems and Schizophrenia","volume":"12","author":"LaCrosse","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"B64","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1176\/ajp.149.5.689","article-title":"Weight gain among schizophrenic patients treated with clozapine","volume":"149","author":"Lamberti","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"B65","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4088\/JCP.v64n0314","article-title":"Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated Schizophrenia","volume":"64","author":"Lane","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e67133","DOI":"10.1371\/journal.pone.0067133","article-title":"Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the nordic countries","volume":"8","author":"Laursen","year":"2013","journal-title":"PLoS ONE"},{"key":"B67","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1176\/ajp.149.1.68","article-title":"Clozapine-induced weight gain: prevalence and clinical relevance","volume":"149","author":"Leadbetter","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"B68","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/sj.mp.4002133","article-title":"Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?","volume":"14","author":"Le Hellard","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"B69","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/mp.2011.109","article-title":"Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications","volume":"17","author":"Lett","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of Antipsychotic drugs in Patients with chronic Schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.schres.2012.09.019","article-title":"Relationship between metabolic syndrome and cognition in patients with schizophrenia","volume":"142","author":"Lindenmayer","year":"2012","journal-title":"Schizophr. Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1038\/nutd.2013.38","article-title":"Effect of insulin on excitatory synaptic transmission onto dopamine neurons of the ventral tegmental area in a mouse model of hyperinsulinemia","volume":"3","author":"Liu","year":"2013","journal-title":"Nutr. Diabetes"},{"key":"B73","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/ng.140","article-title":"Common variants near MC4R are associated with fat mass, weight and risk of obesity","volume":"40","author":"Loos","year":"2008","journal-title":"Nat. Genet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/npp.2010.21","article-title":"Effectiveness of medications used to Attenuate Antipsychotic-related weight gain and Metabolic Abnormalities: a systematic review and meta-analysis","volume":"35","author":"Maayan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-004-1641-y","article-title":"Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study","volume":"48","author":"Mackin","year":"2005","journal-title":"Diabetologia"},{"key":"B76","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/archgenpsychiatry.2012.191","article-title":"Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug\u2013induced weight gain","volume":"69","author":"Malhotra","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0920-9964(01)00326-7","article-title":"Clozapine-induced weight gain predicts improvement in psychopathology","volume":"59","author":"Meltzer","year":"2003","journal-title":"Schizophr. Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1592\/phco.29.6.725","article-title":"Management of atypical Antipsychotic drug-induced weight gain: focus on metformin","volume":"29","author":"Miller","year":"2009","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/PGPM.S11866","article-title":"Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gain","volume":"4","author":"Mueller","year":"2011","journal-title":"Pharmacogenomics Pers. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"CD006629","DOI":"10.1002\/14651858.CD006629.pub2","article-title":"Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems","volume":"8","author":"Mukundan","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neulet.2004.12.037","article-title":"The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia","volume":"379","author":"M\u00fcller","year":"2005","journal-title":"Neurosci. Lett"},{"key":"B83","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0306-4530(02)00114-2","article-title":"A review of the effect of atypical antipsychotics on weight","volume":"28","author":"Nasrallah","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/01.jcp.0000142282.62336.e9","article-title":"Atypical Antipsychotics and Metabolic Dysregulation","volume":"24","author":"Nasrallah","year":"2004","journal-title":"J. Clin. Psychopharmacol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/2647","article-title":"Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene","volume":"4","author":"Nonogaki","year":"1998","journal-title":"Nat. Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.psyneuen.2014.08.017","article-title":"Serum leptin and its relationship with psychopathology in schizophrenia","volume":"50","author":"Nurjono","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.diabet.2008.03.003","article-title":"Insulin sensitivity, adjusted \u03b2-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study","volume":"34","author":"Oriot","year":"2008","journal-title":"Diabetes Metab"},{"key":"B88","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":"Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study","volume":"111","author":"Patel","year":"2009","journal-title":"Schizophr. Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/JCP.0b013e3181fae248","article-title":"Effect of FTO, SH2B1, LEP, and LEPR Polymorphisms on weight gain associated with Antipsychotic treatment","volume":"30","author":"Perez-Iglesias","year":"2010","journal-title":"J. Clin. Psychopharmacol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/BF01561635","article-title":"Changes in weight in patients receiving a \u201ctranquilizing\u201d drug","volume":"32","author":"Planansky","year":"1958","journal-title":"Psychiatr. Q"},{"key":"B91","first-page":"53","article-title":"Weight changes in relation to the characteristics of patients on chlorpromazine","volume":"20","author":"Planansky","year":"1959","journal-title":"J. Clin. Exp. Psychopathol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1080\/00048670701689428","article-title":"Management of Antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme","volume":"41","author":"Poulin","year":"2007","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1176\/appi.ajp.159.6.1058","article-title":"Olanzapine-induced weight gain in patients with first-episode Schizophrenia: a double-blind, Placebo-controlled study of Fluoxetine addition","volume":"159","author":"Poyurovsky","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"B94","first-page":"331","article-title":"Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment","volume":"32","author":"Procyshyn","year":"2007","journal-title":"J. Psychiatry Neurosci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.schres.2014.09.038","article-title":"Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial","volume":"160","author":"Ramsey","year":"2014","journal-title":"Schizophr. Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","article-title":"Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study","volume":"41","author":"Ratzoni","year":"2002","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1017\/S1461145712001435","article-title":"The obesity risk gene FTO influences body mass in chronic schizophrenia but not initial antipsychotic drug-induced weight gain in first-episode patients","volume":"16","author":"Reynolds","year":"2012","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","article-title":"Atypical Antipsychotic-Induced Weight Gain","volume":"25","author":"Roerig","year":"2011","journal-title":"CNS Drugs"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/sj.npp.1301541","article-title":"Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers","volume":"33","author":"Sacher","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0065-2423(09)48004-1","article-title":"Chapter 4 melanocortin-4 receptor mutations in obesity","volume":"48","author":"Santini","year":"2009","journal-title":"Adv. Clin. Chem."},{"key":"B101","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.1523\/JNEUROSCI.2739-05.2005","article-title":"Insulin Inhibits Neuropeptide Y Gene Expression in the Arcuate Nucleus through GABAergic Systems","volume":"25","author":"Sato","year":"2005","journal-title":"J. Neurosci"},{"key":"B102","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/schbul\/sbn104","article-title":"differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation","volume":"36","author":"Savoy","year":"2008","journal-title":"Schizophr. Bull"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1038\/tp.2012.3","article-title":"Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients","volume":"2","author":"Schwarz","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"B104","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s11920-014-0473-9","article-title":"Antipsychotic Induced weight gain: genetics, epigenetics, and biomarkers reviewed","volume":"16","author":"Shams","year":"2014","journal-title":"Curr. Psychiatry Rep"},{"key":"B105","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.psychres.2010.07.012","article-title":"Relation between weight gain and clinical improvement: Is there a metabolic threshold for second generation antipsychotics?","volume":"186","author":"Sharma","year":"2011","journal-title":"Psychiatry Res"},{"key":"B106","first-page":"145","article-title":"Leptin-2548G\/A gene polymorphism in association with antipsychotic-induced weight gain: a meta-analysis study","volume":"26","author":"Shen","year":"2014","journal-title":"Psychiatr. Danub"},{"key":"B107","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000356231","article-title":"Fat Mass- and Obesity-Associated (FTO) gene and Antipsychotic-induced weight gain: an association study","volume":"69","author":"Shing","year":"2014","journal-title":"Neuropsychobiology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0033-3182(70)71577-6","article-title":"Weight as a correlate of clinical response to psychotropic drugs","volume":"11","author":"Singh","year":"1970","journal-title":"Psychosomatics"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","article-title":"Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat","volume":"51","author":"Smith","year":"2008","journal-title":"Diabetologia"},{"key":"B110","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neures.2013.07.003","article-title":"Relationships between serum leptin level and severity of positive symptoms in schizophrenia","volume":"77","author":"Takayanagi","year":"2013","journal-title":"Neurosci. Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"62","author":"Teff","year":"2013","journal-title":"Diabetes"},{"key":"B112","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JCP.0b013e31827d145a","article-title":"Association of a functional polymorphism in Neuropeptide y with Antipsychotic-induced weight gain in Schizophrenia patients","volume":"33","author":"Tiwari","year":"2013","journal-title":"J. Clin. Psychopharmacol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/npp.2009.235","article-title":"A Common Polymorphism in the Cannabinoid Receptor 1 (CNR1) Gene is Associated with Antipsychotic-Induced Weight Gain in Schizophrenia","volume":"35","author":"Tiwari","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"B114","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","article-title":"Metabolic side effects of antipsychotic medication","volume":"61","author":"Tschoner","year":"2007","journal-title":"Int. J. Clin. Pract"},{"key":"B116","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000100981","article-title":"Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation","volume":"85","author":"Tulipano","year":"2007","journal-title":"Neuroendocrinology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/sj.npp.1380224","article-title":"Clozapine and weight gain-Association with clinical response and long-term course","volume":"11","author":"Umbricht","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/WNF.0b013e3181fa2a6f","article-title":"A longitudinal study on the impact of Antipsychotic treatment on Serum Leptin in Schizophrenia","volume":"33","author":"Venkatasubramanian","year":"2010","journal-title":"Clin. Neuropharmacol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1530\/EJE-09-0433","article-title":"Short-term treatment with Olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets","volume":"162","author":"Vidarsdottir","year":"2010","journal-title":"Eur. J. Endocrinol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients with Chronic Schizophrenia and Schizoaffective Disorder","volume":"159","author":"Volavka","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"B121","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/00004714-199908000-00006","article-title":"Weight gain: side effect of atypical neuroleptics?","volume":"19","author":"Wetterling","year":"1999","journal-title":"J. Clin. Psychopharmacol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S0006-3223(98)00100-0","article-title":"Novel antipsychotics and new onset diabetes","volume":"44","author":"Wirshing","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e107116","DOI":"10.1371\/journal.pone.0107116","article-title":"An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine","volume":"9","author":"Wu","year":"2014","journal-title":"PloS ONE"},{"key":"B124","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cca.2012.12.007","article-title":"Role of leptin and adiponectin in insulin resistance","volume":"417","author":"Yadav","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"B125","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1744-9081-8-11","article-title":"Association between Ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients","volume":"8","author":"Yang","year":"2012","journal-title":"Behav. Brain Funct"},{"key":"B126","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/ijo.2014.79","article-title":"Association between MC4R rs17782313 polymorphism and overeating behaviors","volume":"39","author":"Yilmaz","year":"2014","journal-title":"Int. J. Obes"},{"key":"B127","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1176\/appi.ajp.2009.09040598","article-title":"D2Receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis","volume":"167","author":"Zhang","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/schbul\/sbv116","article-title":"Association of a Schizophrenia Risk variant at the DRD2 locus with Antipsychotic treatment response in First-Episode Psychosis","volume":"41","author":"Zhang","year":"2015","journal-title":"Schizophr. Bull"},{"key":"B129","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1192\/bjp.184.1.58","article-title":"Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: Magnetic resonance imaging study of previously untreated people with schizophrenia","volume":"184","author":"Zhang","year":"2003","journal-title":"Br. J. Psychiatry"},{"key":"B130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1192\/bjp.184.1.58","article-title":"Effects of antipsychotics on fat deposition and changes in leptin and insulin levels","volume":"184","author":"Zhang","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2006.02.009","article-title":"Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction","volume":"84","author":"Zhao","year":"2006","journal-title":"Schizophr. Res"},{"key":"B132","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/01.HYP.0000231552.10054.aa","article-title":"Thiazide Diuretics, Potassium, and the Development of diabetes: a quantitative review","volume":"48","author":"Zillich","year":"2006","journal-title":"Hypertension"},{"key":"B133","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1192\/bjp.187.6.537","article-title":"Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol","volume":"187","author":"Zipursky","year":"2005","journal-title":"Br. J. Psychiatry"}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fnins.2017.00741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T13:48:55Z","timestamp":1526392135000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fnins.2017.00741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,22]]},"references-count":133,"alternative-id":["10.3389\/fnins.2017.00741"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2017.00741","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,22]]},"article-number":"741"}}